# Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

> **NCT02960204** · PHASE2 · COMPLETED · sponsor: **Histogen** · enrollment: 263 (actual)

## Conditions studied

- Cirrhosis
- Portal Hypertension
- Non-alcoholic Steatohepatitis

## Interventions

- **DRUG:** Emricasan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02960204
- **Lead sponsor:** Histogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-17
- **Primary completion:** 2018-10-02
- **Final completion:** 2019-04-08
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2022-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02960204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02960204, "Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02960204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*